Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania

Bibliography

• Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005;7(Suppl 4):21-33
   Google Scholar
• Spier SA. Use of atypical antipsychotics: observations from clinical practice. J Clin Psychiatry 2006;67:490-1
   Google Scholar
• Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of veterans affairs. J Clin Psychiatry 2009;70:906-12
   PubMed Web of Science ®Google Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 1998;59(Suppl 12):41-5
   Google Scholar
• Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 2004;16:3-13
   PubMedGoogle Scholar
• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9
   PubMed Web of Science ®Google Scholar
• Seemuller F, Forsthoff A, Dittmann S, The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf 2005;4:849-68
   PubMedGoogle Scholar
• Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-59
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-43
   PubMed Web of Science ®Google Scholar
• Correll CU. Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health 2009;12:93
   Google Scholar
• Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 2008;69(Suppl 4):21-5
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
   PubMed Web of Science ®Google Scholar
• Kane J, Canas F, Kramer M, Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L, Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
   PubMed Web of Science ®Google Scholar
• Tzimos A, Samokhvalov V, Kramer M, Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16:31-43
   PubMed Web of Science ®Google Scholar
• Kramer M, Simpson G, Maciulis V, Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharm 2007;27:6-14
   PubMed Web of Science ®Google Scholar
• Janssen LPJ, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.,. Invega (R), paliperidone extended-release prescribing information. Titusville, NJ 2010 (revised)
   Google Scholar
• Boom S, Talluri K, Janssens L, Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009;49:1318-30
   PubMed Web of Science ®Google Scholar
• Karlsson P, Dencker E, Mannaert E, Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res 2006;81(Suppl 1):85-6
   Google Scholar
• Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Schotte A, Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):S40-54
   Google Scholar
• Rossenu S, Mannaert E, Hargarter L, D2-Receptor occupancies and corresponding plasma concentrations: a comparison of paliperidone extended-release (ER) with risperidone immediate-release (IR). 26th Symposium of the Working Group for Neuropsychopharmacology and Pharmacopsychiatry (AGNP – Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie) 7 – 10 October 2009;42:Munich, Germany. Pharmacopsychiatry 2009;42:238
   Google Scholar
• Vermeir M, Naessens I, Remmerie B, Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-79
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Cleton A, Herben V, The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009;42:158-63
   PubMed Web of Science ®Google Scholar
• Boom S, Thyssen A, Crauwels H, The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009;47:606-16
   PubMed Web of Science ®Google Scholar
• Paulzen M, Orfanos S, Grunder G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry 2010;167:351-2
   PubMed Web of Science ®Google Scholar
• Thyssen A, Cleton A, Talluri K, No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009;24:532-9
   PubMed Web of Science ®Google Scholar
• Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010;71(5):587-98
   Google Scholar
• Canuso C, Schooler N, Carothers J, Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010;30(5):487-95
   Google Scholar
• Berwaerts J, Lane R, Nuamah I, Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2010. In press
   Google Scholar
• Morosini PL, Magliano L, Brambilla L, Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9
   PubMed Web of Science ®Google Scholar
• Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009;113:56-64
   PubMed Web of Science ®Google Scholar
• Canuso CM, Turkoz I, Sheehan JJ, Bossie CA. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Disord 2009;120:193-9
   Google Scholar
• Luthringer R, Staner L, Noel N, A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007;22:299-308
   PubMed Web of Science ®Google Scholar
• Canuso CM, Dirks B, Carothers J, Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166:691-701
   PubMed Web of Science ®Google Scholar
• Grinspan A, Canuso CM, Merriman U, Medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone. 49th Annual New Clinical Drug Evaluation Unit Meeting; 29 June – 2 July 2009, Hollywood, FL, USA
   Google Scholar
• Canuso CM, Youssef EA, Bossie CA, Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-15
   PubMed Web of Science ®Google Scholar
• Turkoz I, Bossie CA, Lindenmayer JP, Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry, submitted
   Google Scholar
• Cleton A, Rossenu S, Talluri K, Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone and an immediate-relase formulation of risperidone. Clin Pharmacol Ther 2007;83:S62
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, DSM-IV. American Psychiatric Press, Washington, D.C.; 1994
   Google Scholar
• Cheniaux E, Landeira-Fernandez J, Lessa Telles L, Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008;106:209-17
   PubMed Web of Science ®Google Scholar
• Potkin SG, Alphs L, Hsu C, Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 2003;54:444-52
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Xu H, Nuamah I, Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2010 July 10. [Epub ahead of print]
   Google Scholar
• Vieta E, Nuamah IF, Lim P, A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010;12:230-43
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson Pharmaceutical Research & Development, LLC. A study to evaluate the effectiveness and safety of extended-release (ER) paliperidone compared with placebo in delaying the recurrence of symptoms in bipolar I disorder. Available from: www.clinicaltrials.gov/NCT00490971 [Last accessed 8 June 2010]
   Google Scholar
• Amatniek J, Mao L, Rodriguez S, Single-arm evaluation of paliperidone extedned-release (ER) in subjects with schizophrenia or schizoaffective disorder and haptic disease. Annual US Psychiatric and Mental Health Congress; 2 – 5 November 2009; Las Vegas, NV, USA
   Google Scholar
• Emsley R, Berwaerts J, Eerdekens M, Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-56
   PubMed Web of Science ®Google Scholar
• Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21:529-32
   PubMed Web of Science ®Google Scholar
• Knegtering R, Baselmans P, Castelein S, Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162:1010-2
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Canuso CM, Youssef E, Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Hum Psychopharmacol 2007;22:326-7; author reply 8
   PubMed Web of Science ®Google Scholar
• Pani L, Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 2009;6:319-31
   PubMed Web of Science ®Google Scholar
• Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009;29:64-73
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
   PubMed Web of Science ®Google Scholar
• Kane JM, Barrett EJ, Casey DE, Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004;65:1447-55
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(5 Suppl 1):S7-14
   Google Scholar
• Correll CU, Manu P, Olshanskiy V, Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Chiu E, Harrigan S, The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18:432-40
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Tollefson G, Tohen M, Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404
   PubMed Web of Science ®Google Scholar
• Perlis RH, Welge JA, Vornik LA, Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-16
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007;7:40
   PubMed Web of Science ®Google Scholar
• Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007;13(7 Suppl):S178-88
   Google Scholar
• Letmaier M, Schreinzer D, Reinfried L, Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting. Int J Neuropsychopharmacol 2006;9:529-37
   PubMedGoogle Scholar
• Fuller BE, Rodriguez VL, Linke A, Prevalence of liver diseases in veterans with bipolar disorder or schizophrenia. American Psychiatric Association 162nd Annual Meeting; 16 – 21 May 2009; San Francisco, CA, USA
   Google Scholar
• Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006;68:684-91
   PubMed Web of Science ®Google Scholar
• Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 2006;21:1133-7
   PubMed Web of Science ®Google Scholar
• Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005;66(Suppl 6):27-33
   Google Scholar